NHS Mounjaro weight loss: who qualifies, what the phases mean, and what to do if you don't

The myth: 'Mounjaro is available on the NHS for weight loss now, I just need to ask my GP'

This is the question our prescribers hear most weeks, in one form or another. The short answer is: NICE did recommend tirzepatide for NHS use, and that is a genuinely significant development. But recommendation and access are two different things. The NHS rolls this out in timed cohorts, and the entry requirements for each cohort are demanding.

Whether you qualify under NHS rules depends on where the rollout currently sits. As of June 2025, NHS England's first cohort requires a BMI of 40 or above and four or more of five specific conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. That is an extremely narrow group. The second cohort (BMI 35–39.9 with four or more of the same conditions) activated in June 2026. A third, broader cohort is expected around March 2027. For South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, BMI thresholds throughout the programme are 2.5 kg/m² lower, so 37.5, not 40, and so on. Even meeting the numbers on paper does not guarantee access: your GP practice must have opted into the new prescribing arrangements, and availability varies considerably by area. Every NHS patient also needs to take part in wrap-around lifestyle support as a condition of treatment.

NICE's full recommendations for tirzepatide (TA1026) set out the clinical criteria in detail, including the comorbidity list and the review points if weight loss is insufficient after six months at the highest tolerated dose.

What NICE actually decided, and what the NHS is commissioning

NICE published its appraisal of tirzepatide (TA1026) on 23 December 2024, updated 1 September 2025. The recommendation covers adults with a BMI of 35 or above plus at least one weight-related comorbidity, used alongside a reduced-calorie diet and increased activity. That is the long-term licensing target. NHS commissioning is, however, deliberately sequenced to start with the highest-need patients first and expand as capacity allows.

So Mounjaro for weight loss on the NHS is real, it is just arriving in stages, not all at once. GP practices can prescribe under the updated 2026/27 contract, but participation is voluntary, and waiting lists within eligible groups are already forming. If your BMI is 32 or your only condition is raised cholesterol, the realistic options currently sit outside the NHS route.

It is also worth being clear about what the NHS is not providing: Ozempic and Rybelsus are semaglutide medicines licensed for type 2 diabetes, not weight loss. Mounjaro is the only tirzepatide medicine licensed in the UK, and the only one covered by this NICE guidance.

Private prescription: the route most people end up taking

For the large majority of people who don't meet the current NHS thresholds, or who do qualify but face a long wait, a private prescription is the practical alternative. Private prescribing for Mounjaro follows the licensed eligibility set out in the product's authorisation: adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as prediabetes, hypertension, high cholesterol, or obstructive sleep apnoea.

The process through a regulated online pharmacy involves a clinical consultation, identity and weight verification, and a prescriber's review. If you are wondering whether Mounjaro can be purchased over the counter, the straightforward answer is no, as a valid prescription is always required. You can check any online pharmacy on the GPhC register at pharmacyregulation.org before you hand over any personal or payment details.

Private treatment costs more than an NHS prescription, and those who want to buy Mounjaro for weight loss online will find that prices vary between providers. Since Eli Lilly raised its UK list price in September 2025, private Mounjaro has typically ranged from around £149 to £375 per month depending on dose and clinic. A legitimate price includes the consultation, prescription and clinical oversight, not just the pen.

Safety and what to expect on treatment

The most common side effects of Mounjaro are gastrointestinal: nausea, loose stools, constipation, indigestion and reduced appetite, particularly after starting or after a dose increase. These usually settle within a week or two. Treatment begins at 2.5 mg, a tolerability dose designed to let your system adjust before the prescriber moves you up through 5, 7.5, 10, 12.5 and 15 mg as clinically appropriate.

Seek urgent medical help for severe stomach pain that spreads to your back (a potential sign of pancreatitis), significant vomiting that prevents you keeping fluids down, or any signs of a serious allergic reaction. Safety considerations around Mounjaro are covered in detail separately, including the MHRA's January 2026 communications on pancreatitis risk. Suspected side effects from any source can be reported at yellowcard.mhra.gov.uk.

Mounjaro is not licensed for use in pregnancy, breastfeeding, or for anyone trying to conceive, and it is not licensed for under-18s. Women taking oral contraceptives should discuss adding a non-oral method during the first four weeks of treatment and for four weeks after each dose increase, as absorption of the pill may be reduced. If surgery is planned, tell the anaesthetist you are taking this medicine.

If you're weighing up private treatment while you wait for NHS access to reach your cohort, checking your eligibility with our prescribers is a good place to start. There's no commitment, and the consultation is free.